These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
436 related articles for article (PubMed ID: 27018748)
41. Tetanus-diphtheria-acellular pertussis vaccination of adults in the USA. Gidengil CA; Sandora TJ; Lee GM Expert Rev Vaccines; 2008 Jul; 7(5):621-34. PubMed ID: 18564017 [TBL] [Abstract][Full Text] [Related]
42. Safety review of tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccines (Tdap) in adults aged ≥65 years, Vaccine Adverse Event reporting System (VAERS), United States, September 2010-December 2018. Haber P; Moro PL; Ng C; Dores GM; Perez-Vilar S; Marquez PL; Cano M Vaccine; 2020 Feb; 38(6):1476-1480. PubMed ID: 31883809 [TBL] [Abstract][Full Text] [Related]
43. Barriers to Receipt of Prenatal Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Among Mothers of Infants Aged <4 Months with Pertussis - California, 2016. New S; Winter K; Boyte R; Harriman K; Gutman A; Christiansen A; Royce S MMWR Morb Mortal Wkly Rep; 2018 Sep; 67(38):1068-1071. PubMed ID: 30260942 [TBL] [Abstract][Full Text] [Related]
44. Post-licensure safety surveillance study of routine use of tetanus toxoid, reduced diphtheria toxoid and 5-component acellular pertussis vaccine. Baxter R; Hansen J; Timbol J; Pool V; Greenberg DP; Johnson DR; Decker MD Hum Vaccin Immunother; 2016 Nov; 12(11):2742-2748. PubMed ID: 27388557 [TBL] [Abstract][Full Text] [Related]
45. Maternal Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccination During Pregnancy: Impact on Infant Anti-Pertussis Antibody Concentrations by Maternal Pertussis Priming Series. Havers FP; Skoff TH; Rench MA; Epperson M; Rajam G; Schiffer J; Hariri S; Swaim LS; Baker CJ; Healy CM Clin Infect Dis; 2023 Feb; 76(3):e1087-e1093. PubMed ID: 35642525 [TBL] [Abstract][Full Text] [Related]
46. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <12 months --- Advisory Committee on Immunization Practices (ACIP), 2011. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2011 Oct; 60(41):1424-6. PubMed ID: 22012116 [TBL] [Abstract][Full Text] [Related]
47. Acellular pertussis vaccine for adolescents. de Carvalho AP; Pereira EM J Pediatr (Rio J); 2006 Jul; 82(3 Suppl):S15-24. PubMed ID: 16786100 [TBL] [Abstract][Full Text] [Related]
49. A placebo-controlled trial of a pertussis-toxoid vaccine. Trollfors B; Taranger J; Lagergård T; Lind L; Sundh V; Zackrisson G; Lowe CU; Blackwelder W; Robbins JB N Engl J Med; 1995 Oct; 333(16):1045-50. PubMed ID: 7675047 [TBL] [Abstract][Full Text] [Related]
50. A 6-year Prospective, Observational, Multi-Center Post-Marketing Surveillance of the Safety of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis (Tdap) Vaccine in Korea. Park HJ; Kim SJ; Song R; Chen J; Kim JH; Devadiga R; Kang HC J Korean Med Sci; 2019 Apr; 34(12):e105. PubMed ID: 30940999 [TBL] [Abstract][Full Text] [Related]
51. Predictors of tetanus-diphtheria- acellular pertussis vaccination among adults receiving tetanus vaccine in the United States: data from the 2008 national health interview survey. Johns TL; Roetzheim R; Chen R J Prim Care Community Health; 2013 Apr; 4(2):95-100. PubMed ID: 23799715 [TBL] [Abstract][Full Text] [Related]
52. Association of a Best-Practice Alert and Prenatal Administration With Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccination Rates. Morgan JL; Baggari SR; Chung W; Ritch J; McIntire DD; Sheffield JS Obstet Gynecol; 2015 Aug; 126(2):333-337. PubMed ID: 26241423 [TBL] [Abstract][Full Text] [Related]
53. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001. Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR; Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582 [TBL] [Abstract][Full Text] [Related]
54. Additional recommendations for use of tetanus toxoid, reduced-content diphtheria toxoid, and acellular pertussis vaccine (Tdap). ; Pediatrics; 2011 Oct; 128(4):809-12. PubMed ID: 21949151 [TBL] [Abstract][Full Text] [Related]
55. Predictors of Low Uptake of Prenatal Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Immunization in Privately Insured Women in the United States. Butler AM; Layton JB; Li D; Hudgens MG; Boggess KA; McGrath LJ; Weber DJ; Becker-Dreps S Obstet Gynecol; 2017 Apr; 129(4):629-637. PubMed ID: 28277354 [TBL] [Abstract][Full Text] [Related]
56. The Epidemiology of Nationally Reported Pertussis in the United States, 2000-2016. Skoff TH; Hadler S; Hariri S Clin Infect Dis; 2019 May; 68(10):1634-1640. PubMed ID: 30169627 [TBL] [Abstract][Full Text] [Related]
57. Immunogenicity and safety of a tetanus toxoid, reduced diphtheria toxoid and three-component acellular pertussis vaccine in adults 19-64 years of age. Blatter M; Friedland LR; Weston WM; Li P; Howe B Vaccine; 2009 Jan; 27(5):765-72. PubMed ID: 19041352 [TBL] [Abstract][Full Text] [Related]
58. Extensive swelling reaction associated with diphtheria and tetanus toxoids and acellular pertussis vaccine. Sekaran NK; Edwards KM Pediatr Infect Dis J; 2006 Apr; 25(4):374-5. PubMed ID: 16567996 [TBL] [Abstract][Full Text] [Related]
59. Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults. Grimprel E; von Sonnenburg F; Sänger R; Abitbol V; Wolter JM; Schuerman LM Vaccine; 2005 May; 23(28):3657-67. PubMed ID: 15882526 [TBL] [Abstract][Full Text] [Related]
60. [COMPARATIVE CHARACTERISTICS OF PERTUSSIS-DIPHTHERIA, PERTUSSIS-DIPHTHERIA-TETANUS AND SORBED PERTUSSIS-DIPHTERIA-TETANUS VACCINES IN THE IMMUNIZATION OF CHILDREN]. REZNIK BIa Zh Mikrobiol Epidemiol Immunobiol; 1963 Dec; 40():13-7. PubMed ID: 14151776 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]